CompanyGraph
What stands out
- Dividend several times the last twelve months' earnings
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleMarket cap is $449.45B, higher than 95% of all stocks globally
- FinancialsHigh earnings quality
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
What stands out
- Dividend several times the last twelve months' earnings
Dividends view
Yield
2.68%Below 5Y avg (3.60%)
Annual Rate
USD 6.92Paid quarterly
Payout Ratio
326.0%High
Consecutive Growth
12 yrStrong track record
Paying Dividends
14 yr
Payback Period
38.8 yr
Last Ex-Dividend
Jul 15, 2026
Last Payment
Aug 14, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
449.45BUSDvs all stocks (USD)
Trailing P/E
124.09xRevenue (TTM)
62.82BUSDvs all stocks (USD)
Profit Margin
5.79%Beta
0.2830xvs all stocks
52-Week Change
36.39%vs all stocks
Forward Annual Dividend Yield
2.68%vs all stocks
Market Capitalization
449.45BUSDvs all stocks (USD)
Enterprise Value
513.02BUSDvs all stocks (USD)
Trailing P/E
124.09xForward P/E
15.63xPEG Ratio
-2.70xPrice to Sales (TTM)
7.15xEnterprise to Revenue
8.17xEnterprise to EBITDA
17.15xGross Margin
71.88%Profit Margin
5.79%Operating Margin
32.16%Return on Assets (TTM)
10.03%Revenue (TTM)
62.82BUSDvs all stocks (USD)
Revenue per Share (TTM)
35.50USDUpdated Jul 17, 2026Quarterly Revenue Growth
12.40%Gross Profit (TTM)
45.25BUSDvs all stocks (USD)
EBITDA (TTM)
22.49BUSDvs all stocks (USD)
Net Income (TTM)
3.60BUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-46.00%Operating Cash Flow (TTM)
21.22BUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
20.81BUSDvs all stocks (USD)
Forward Annual Dividend Rate
6.92USDUpdated Jul 17, 2026Forward Annual Dividend Yield
2.68%vs all stocks
Trailing Annual Dividend Rate
6.83USDUpdated Jul 17, 2026Trailing Annual Dividend Yield
2.65%vs all stocks
5-Year Average Dividend Yield
3.60%vs all stocks
Payout Ratio
325.98%Minority Interest (Equity)
42.00MUSDFY2025 · Dec 31, 2025Revenue
61.16BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
18.20BUSDFY2025 · Dec 31, 2025Gross Profit
42.96BUSDFY2025 · Dec 31, 2025Operating Income
20.09BUSDvs all stocks (USD)
Pre-tax Income
6.60BUSDFY2025 · Dec 31, 2025Income Tax Expense
2.36BUSDFY2025 · Dec 31, 2025Net Income
4.23BUSDFY2025 · Dec 31, 2025EBIT
9.49BUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
22.70BUSDFY2025 · Dec 31, 2025Research & Development
9.10BUSDFY2025 · Dec 31, 2025Selling, General & Administrative
14.01BUSDFY2025 · Dec 31, 2025Other Operating Expenses
-241.00MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
266.00MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
2.89BUSDFY2025 · Dec 31, 2025EPS (Basic)
2.37USDFY2025 · Dec 31, 2025EPS (Diluted)
2.37USDFY2025 · Dec 31, 2025Basic Shares Outstanding
1.77BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.77BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
4.23BUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
-7.00MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
40.00MUSDFY2025 · Dec 31, 2025Operating Cash Flow
19.94BUSDFY2025 · Dec 31, 2025Free Cash Flow
18.73BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
5.23BUSDFY2025 · Dec 31, 2025Income Tax Paid
3.63BUSDFY2025 · Dec 31, 2025Interest Paid
3.00BUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
4.23BUSDFY2025 · Dec 31, 2025Depreciation & Amortization
8.14BUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-492.00MUSDFY2025 · Dec 31, 2025Stock-based Compensation
955.00MUSDFY2025 · Dec 31, 2025Other Non-cash Items
8.64BUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-1.49BUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
951.00MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-996.00MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.21BUSDFY2025 · Dec 31, 2025Net Acquisitions
-5.44BUSDFY2025 · Dec 31, 2025Purchase of Investments
-35.00MUSDFY2025 · Dec 31, 2025Sale of Investments
76.00MUSDFY2025 · Dec 31, 2025Other Investing Activity
-29.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-6.64BUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
3.99BUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-9.60BUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
2.50BUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-980.00MUSDFY2025 · Dec 31, 2025Common Dividends Paid
-11.66BUSDFY2025 · Dec 31, 2025Other Financing Charges
45.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-15.69BUSDFY2025 · Dec 31, 2025Shares Outstanding
1.77BSharesUpdated Jul 17, 2026Float Shares
1.76BSharesUpdated Jul 17, 2026Shares Short
21.90MSharesUpdated Jul 17, 2026Short Ratio
2.52daysvs all stocks
Short % of Shares Outstanding
1.38%vs all stocks
% Held by Insiders
0.11%vs all stocks
% Held by Institutions
76.87%vs all stocks
Total Cash (MRQ)
9.39BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.32USDUpdated Jul 17, 2026Total Debt (MRQ)
72.91BUSDvs all stocks (USD)
Current Ratio (MRQ)
0.7960xBook Value per Share (MRQ)
-3.77USDUpdated Jul 17, 2026Total Assets
133.96BUSDvs all stocks (USD)
Total Current Assets
29.06BUSDFY2025 · Dec 31, 2025Total Liabilities
137.19BUSDFY2025 · Dec 31, 2025Total Non-current Assets
104.90BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
93.90BUSDFY2025 · Dec 31, 2025Total Current Liabilities
43.29BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
5.23BUSDFY2025 · Dec 31, 2025Other Short-term Investments
28.00MUSDFY2025 · Dec 31, 2025Accounts Receivable
12.59BUSDFY2025 · Dec 31, 2025Inventory
4.95BUSDFY2025 · Dec 31, 2025Accounts Payable
3.59BUSDFY2025 · Dec 31, 2025Short-term Debt
8.55BUSDFY2025 · Dec 31, 2025Long-term Debt
58.94BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
30.80BUSDFY2025 · Dec 31, 2025Common Stock (Book)
18.00MUSDFY2025 · Dec 31, 2025Retained Earnings
-15.49BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-3.23BUSDvs all stocks (USD)
Treasury Stock
9.15BUSDFY2025 · Dec 31, 202552-Week Low
184.63USDUpdated Jul 17, 202652-Week High
261.64USDUpdated Jul 17, 202652-Week Change
36.39%vs all stocks
Beta
0.2830xvs all stocks
50-Day MA
227.14USDUpdated Jul 17, 2026200-Day MA
223.34USDUpdated Jul 17, 2026Avg 10-Day Volume
6.31MSharesUpdated Jul 17, 2026Avg 30-Day Volume
8.05MSharesUpdated Jul 17, 2026Diluted EPS (TTM)
2.05USDUpdated Jul 17, 2026Other Income / Expense
-10.87BUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Dividend several times the last twelve months' earningsSignificant
Payout Ratio: 3.26Dividend per Share: 6.83Earnings per Share: 2.05
High gross margins eroded by operating costsNotable
Gross Margin: 0.72Profit Margin: 0.06
Financial Health
High earnings qualityNotable
Earnings Quality Score: 2.17
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Scale
Market cap is $449.45B, higher than 95% of all stocks globallySignificant
Market cap (USD): 449,454,425,734Global P95: 25,614,208,870.135
Revenue is $62.82B, higher than 95% of all stocks globallySignificant
Revenue (USD): 62,819,000,320Global P95: 14,667,937,174.886
Levered free cash flow is $20.81B, higher than 95% of all stocks globallySignificant
Levered free cash flow (USD): 20,811,624,448Global P95: 1,123,592,359.78
Companies that share the same coordination system — how they create, deliver, or capture value.
Roche Holding AG Genussscheine
Tier 1ProductionApproval-Gated PipelineRuleRisk
Johnson & Johnson
Tier 1ProductionApproval-Gated PipelineRuleFlow
Merck & Co., Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Novartis AG
Tier 1ProductionApproval-Gated PipelineRuleRisk
AstraZeneca PLC
Tier 1ProductionApproval-Gated PipelineRuleFlow
Amgen Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Eli Lilly and Company
Tier 1ProductionApproval-Gated PipelineRuleRisk
Abbott Laboratories
Tier 1ProductionApproval-Gated PipelineRuleFlow
Gilead Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Novo Nordisk A/S
Tier 1ProductionApproval-Gated PipelineRule